Phase 2 Brain Cancer Trial, Recruiting NCT06687681 Sponsor: Marzieh Ebrahimi Condition: Brain Cancer
Back to Brain Cancer

Phase 2 Brain Cancer Trial, Recruiting

NCT06687681
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been newly diagnosed with a grade 3 or 4 brain tumour, falling into one of these specific types: Astrocytoma (IDH-mutant), Oligodendroglioma (IDH-mutant), Glioblastoma (IDH-wild type), Diffuse midline glioma, Diffuse hemispheric glioma, or Diffuse pediatric-type high-grade glioma (IDH-wild type)
  • People between 3 and 60 years of age, of any sex
  • People with a functional ability score above 60 on the Lansky or Karnofsky scale, meaning they are reasonably able to carry out daily activities (confirm with trial site)
  • People, or their parents or legal guardians (in the case of children), who have given written informed consent to participate
  • People with a haemoglobin (a measure of red blood cells) above 10 g/dL
  • People with an adequate level of infection-fighting white blood cells (absolute granulocyte count above 500 per microlitre of blood)
  • People with a platelet count above 50,000 per microlitre of blood, indicating reasonable ability for blood to clot
  • People with blood clotting test results within an acceptable range (INR below 2, and PTT less than 1.5 times the upper limit of normal)
  • People with liver function test results within an acceptable range (bilirubin less than 1.5 times the upper limit of normal, and liver enzymes ALT and AST less than 3 times the upper limit of normal)
  • People with kidney function results within an acceptable range (creatinine less than 1.5 times the upper limit of normal)

Who may not be able to join:

  • People who show signs of radiation-related tissue damage (radionecrosis) on a brain MRI or MRS scan
  • People whose medical condition is too unstable or urgent to tolerate a new treatment
  • People with a history of any other type of cancer
  • People with a history of immune system disorders or conditions that weaken the immune system
  • People whose brain fluid drainage device (cerebral shunt) has ruptured, or who are unable to have a lumbar puncture (spinal tap) performed
  • People who are pregnant
  • People with a history of poorly controlled long-term illnesses such as diabetes, heart failure, liver cirrhosis, or chronic kidney disease

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +98 21 235 62516

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Marzieh Ebrahimi
Registry
ClinicalTrials.gov
Start date
25 November 2024
Est. completion
25 November 2025

Where this trial is recruiting

Iran

Primary endpoints

To measure tumor response after infusion of intrathecal NK cells

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov